Despite intense efforts, the long-term cure rates of children and adults with acute myeloid leukemia are not satisfactory. Resistance to cytotoxic chemotherapy and apoptosis is the dominant cause of treatment failure. The molecular mechanisms responsible for chemotherapy resistance are poorly understood, hindering the development of therapeutic strategies to induce chemosensitivity. We have found that chemotherapy and apoptosis resistance in high-risk AML requires aberrant phosphorylation of MEF2C, a key transcriptional regulator of leukemia cell growth and survival. The central hypothesis of this proposal is that defining the apoptotic mechanisms dysregulated by aberrant MEF2C signaling will reveal effective therapeutic strategies to overcome treatment resistance. The applicant, who is a New Investigator, will test this hypothesis by investigating the molecular mechanisms of apoptosis resistance in primary human and genetically-engineered mouse leukemias.
Aim 1 will elucidate both transcriptional and cellular mechanisms of therapy resistance, with the goal of identifying MEF2C targets that are necessary and sufficient for chemoresistance.
Aim 2 will pursue the preliminary evidence that MARK family kinases aberrantly phosphorylate MEF2C and devise rational combination strategies to overcome chemotherapy resistance induced by MEF2C phosphorylation. Successful completion of this project is expected to yield molecular mechanisms of aberrant survival and chemotherapy resistance of high-risk AML, thus providing essential insights into a fundamental biological and clinical problem, which can be rapidly translated into clinical trials for patients with this disease.
Children and adults with acute myeloid leukemia (AML) whose cancer cells acquire specific molecular aberrations in signaling and gene control pathways have dismal outcomes with current therapy. The planned research project is relevant to public health because the discovery of how aberrant kinase signaling of transcription factors causes resistance to apoptosis will lead to novel cancer therapeutic insights. The proposed research is highly relevant to the NIH mission and the urgent unmet need of developing therapeutic strategies to overcome apoptosis resistance, thereby blocking chemoresistance that is responsible for the majority of treatment failures of patients with refractory AML.
|Johnson, Darren C; Taabazuing, Cornelius Y; Okondo, Marian C et al. (2018) DPP8/DPP9 inhibitor-induced pyroptosis for treatment of acute myeloid leukemia. Nat Med 24:1151-1156|
|Pronier, Elodie; Cifani, Paolo; Merlinsky, Tiffany R et al. (2018) Targeting the CALR interactome in myeloproliferative neoplasms. JCI Insight 3:|
|Ramaswamy, Kavitha; Forbes, Lauren; Minuesa, Gerard et al. (2018) Peptidomimetic blockade of MYB in acute myeloid leukemia. Nat Commun 9:110|
|Brown, Fiona C; Still, Eric; Koche, Richard P et al. (2018) MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia. Cancer Discov 8:478-497|
|Hoshii, Takayuki; Cifani, Paolo; Feng, Zhaohui et al. (2018) A Non-catalytic Function of SETD1A Regulates Cyclin K and the DNA Damage Response. Cell 172:1007-1021.e17|
|Gutierrez, Alejandro; Kentsis, Alex (2018) Acute myeloid/T-lymphoblastic leukaemia (AMTL): a distinct category of acute leukaemias with common pathogenesis in need of improved therapy. Br J Haematol 180:919-924|
|Cifani, Paolo; Kentsis, Alex (2017) High Sensitivity Quantitative Proteomics Using Automated Multidimensional Nano-flow Chromatography and Accumulated Ion Monitoring on Quadrupole-Orbitrap-Linear Ion Trap Mass Spectrometer. Mol Cell Proteomics 16:2006-2016|
|Cifani, Paolo; Shakiba, Mojdeh; Chhangawala, Sagar et al. (2017) ProteoModlR for functional proteomic analysis. BMC Bioinformatics 18:153|
|Cifani, Paolo; Kentsis, Alex (2017) Towards comprehensive and quantitative proteomics for diagnosis and therapy of human disease. Proteomics 17:|
|Ortiz, Michael V; Kobos, Rachel; Walsh, Michael et al. (2016) Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center. Pediatr Blood Cancer 63:1368-74|